Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 113

Results For "EU"

4826 News Found

Lupin receives tentative approval from USFDA for Oxcarbazepine ER Tablets
Drug Approval | June 09, 2025

Lupin receives tentative approval from USFDA for Oxcarbazepine ER Tablets

Oxcarbazepine ER Tablets (RLD Oxtellar XR) had estimated annual sales of US$ 206 million in the US (IQVIA MAT April 2025)


Health Minister Nadda delivers keynote address at FSSAI’s World Food Safety Day 2025
Policy | June 09, 2025

Health Minister Nadda delivers keynote address at FSSAI’s World Food Safety Day 2025

Launches FSSAI’s inclusive campaign to stop obesity with multilingual, sign language outreach and multi-platform media engagement under Eat Right India programme


Fujifilm rebrands life sciences companies to strengthen position as strategic partners for life
News | June 07, 2025

Fujifilm rebrands life sciences companies to strengthen position as strategic partners for life

Enhanced alignment to better serve customers across the entire drug development lifecycle under the Fujifilm Life Sciences brand umbrella with the tagline Partners for Life


Linerixibat new drug application accepted for review by the USFDA for cholestatic pruritus in patients with PBC
News | June 07, 2025

Linerixibat new drug application accepted for review by the USFDA for cholestatic pruritus in patients with PBC

If approved, linerixibat could address high unmet medical need of patients living with cholestatic pruritus (relentless itch) and related sleep interference


NPPA fixes retail prices for 41 drug combinations
Policy | June 06, 2025

NPPA fixes retail prices for 41 drug combinations

The NPPA has capped prices for 41 drug combinations including diabetes, cholesterol, and sleep disorder treatments


Sun Pharma discontinue development of SCD-044 drug after trial disappointment
Diagnostic Center | June 05, 2025

Sun Pharma discontinue development of SCD-044 drug after trial disappointment

Sun Pharma discontinues work on its experimental skin drug SCD-044 after Phase 2 trial results fall short of goals for treating psoriasis and atopic dermatitis


Bristol Myers Squibb and BioNTech sign up to $11 billion cancer bispecific antibody collaboration
News | June 05, 2025

Bristol Myers Squibb and BioNTech sign up to $11 billion cancer bispecific antibody collaboration

BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types


Allarity announces enrolment of first patient in phase 2 clinical trial protocol of Stenoparib in advanced ovarian cancer
Diagnostic Center | June 05, 2025

Allarity announces enrolment of first patient in phase 2 clinical trial protocol of Stenoparib in advanced ovarian cancer

The newly launched protocol will accelerate the clinical development of stenoparib and its drug-specific Drug Response Predictor (DRP) companion diagnostic (CDx) toward potential FDA approval


Sanofi exercises license extension option to Nurix’s STAT6 program
Biopharma | June 04, 2025

Sanofi exercises license extension option to Nurix’s STAT6 program

his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days